You are here: Industry Insights > CAR-T

News List

Cellular Biomedicine Group Enters Into Strategic Licensing and Collaboration Agreement with a Global Leader in CAR-T Cell Therapy for Patients in China pharmafocusasia
September 29, 2018
Cellular Biomedicine Group Inc today announced it has entered into a strategic licensing and collaboration agreement with Novartis to manufacture and supply the CAR-T cell therapy Kymriah® (tisagenlecleucel) in China. Novartis will be the exclusive holder
Johnson & Johnson CAR-T partner GenScript yo-yos on fake data allegations fiercebiotech
September 29, 2018
Hong Kong, S.A.R., China biotech GenScript has had a turbulent 48 hours, with its shares plummeting yesterday on allegations of data falsification in a CAR-T program, only to rebound after it strongly denied the claims.
NICE rejects CAR-T therapy Kymriah for DLBCL in adults pharmafile
September 20, 2018
The National Institute for health and Care Excellence (NICE) has rejected Novartis’ CAR-T therapy Kymriah for use in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
5 months after launch, Allogene guns for $100M IPO fiercebiotech
September 18, 2018
Allogene licensed its allogeneic CAR-T pipeline from Cellectis by way of Pfizer.
Allogene raises another $120M for off-the-shelf CAR-T programs fiercebiotech
September 07, 2018
Round adds to $300M in startup funding for Allogene (Pixabay/Quincemedia)
IsoPlexis expands in APAC, inks deal with Tekon Biotech biospectrumasia
August 23, 2018
The deal will help the comapny distribute its products in China
CAR-T player Cellectis poaches Stefan Scherer from Novartis fiercebiotech
August 06, 2018
Cellectis has named Stefan Scherer, M.D., Ph.D., as its SVP of clinical development. Scherer joins the off-the-shelf CAR-T pioneer from Novartis, where he headed up U.S. oncology early development and strategy.
Novartis runs into Kymriah production glitch in new DLBCL indication fiercepharma
July 19, 2018
Novartis, whose personalized CAR-T cancer treatment Kymriah won an approval in May to treat relapsed large B-cell lymphoma, said today it has run into some manufacturing issues around that condition.
CHMP recommends Novartis' CAR-T therapy Kymriah for EU approval pharmafile
July 06, 2018
The Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Medicines Agency (EMA) approve Novartis’ CAR-T therapy Kymriah (tisagenlecleucel, formerly CTL019).
CAR-T therapies leap towards EU approval pharmatimes
July 03, 2018
The stage has been set for approval of the first chimeric antigen T-cell therapies (CAR-T) in Europe, after Novartis’ Kymriah and Gilead’s Yescarta both won backing from the Committee for Medicinal Products for Human Use (CHMP).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 13 14 Next page